The importance of nanotechnology and drug carrier systems in pharmacology

Ulku Yerebasan; Baykalir Burcu Gul

doi:10.30574/gscbps.2020.10.2.0018

Authors

Ulku Yerebasan Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Firat University, 23119 Elazig, Turkey.
Baykalir Burcu Gul Department of Nursing, Faculty of Health Sciences, Firat University, 23119 Elazig, Turkey.

DOI:

https://doi.org/10.30574/gscbps.2020.10.2.0018

Keywords:

Nanotechnology, Pharmacology, Carrier system, Targeting

Abstract

Nanotechnology is one of the newest and most interesting areas of recent years. It offers innovations in diagnosis and treatment with the integration of limited size nanoparticles into larger living systems. It was found application in the field of microbiology, vaccine production, wound healing, tissue regeneration, and genetic, especially in pharmacology. It was significantly increased in the life quality of patients compared with traditional methods due to a number of superiorities such as demonstrated tumor specificity especially in the field of oncology, pass the blood brain barrier in neurodegenerative diseases and offer non-invasive alternatives in diabetes. However, there are also some risks of systemic, genetic and cytotoxic. With this study, it was aimed to inform about the status of nanotechnology in the field of pharmacology, advantages and drug carrier systems.

Metrics

Metrics Loading ...

References

Chakravarthi VP and Balaji N. (2010). Applications of nanotechnology in veterinary medicine. Veterinary World, 25, 477-480.

Tatli Seven P, Seven I, Gul Baykalir B, Iflazoglu Mutlu S and Salem AZM. (2018) Nanotechnology and nanopropolis in animal production and Health: an overview. Italian Journal of Animal Science, 1-10.

Sanginario A, Miccoli B and Demarchi D. (2017). Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. Biosensors, 7(1), 1-23.

Mohanraj VJ and Chen Y. (2006). Nanoparticles - a review. Tropical Journal of Pharmaceutical Research, 5(1), 561-573.

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA and Alexander A. (2018). Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release, 281, 139-177.

Srimathi U, Nagarajan V and Chandiramouli R. (2018). Interaction of Imuran, Pentasa and Hyoscyamine drugs and solvent effects on graphdiyne nanotube as a drug. Journal of Molecular Liquids, 265, 199-207.

Wang L, Yao J, Zhang X, Zhang Y, Xu C, Lee RJ, Yu G, Yu B and Teng L. (2018). Delivery of paclitaxel using nanoparticles composed of poly (ethylene oxide)-b-poly(butylene oxide) (PEO-PBO). Colloids Surf B Biointerfaces, 161, 464-470.

Wilczewska AZ, Niemirowicz K, Markiewicz KH and Car H. (2012). Nanoparticles as drug delivery systems. Pharmacological Reports, 64(5), 1020-1037.

Huang B, Abraham WD, Zheng Y, Bustamante Lopez SC, Luo SS and Irvine DJ. (2015). Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Science Translational Medicine, 7(291), 1-21.

Shen B, Ma Y, Yu S and Ji C. (2016). Smart multifunctional magnetic nanoparticle-based drug delivery system for cancer thermo-chemotherapy and intracellular imaging. ACS Applied Materials and Interfaces, 8, 24502-24508.

Ravi Kumar MN. (2000). Nano and microparticles as controlled drug delivery devices. Journal of Pharmacy and Pharmaceutical Sciences, 3(2), 234-258.

Duffin R, Mills NL and Donaldson K. (2007). Nanoparticles-a thoracic toxicology perspective. Yonsei Medical Journal, 48(4), 561-572.

Syed S, Zubair A and Frieri M. (2013). Immune response to nanomaterials: implications for medicine and literature review. Current Allergy and Asthma Reports, 13(1), 50-57.

Petros RA and DeSimone JM. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615-627.

Roger E, Lagarce F, Garcion E and Benoit JP. (2010). Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond), 5(2), 287-306.

Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC and Naidoo D. (2009). Nanotechnological applications for the treatment of neurodegenerative disorders. Progress in Neurobiology, 88, 272-285.

Jain A and Jain SK. (2008). In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. European Journal of Pharmaceutical Sciences, 35(5), 404-416.

Francis MF, Cristea M and Winnik FM. (2005). Exploiting the vitamin B12 pathway to enhance oral drug delivery via polymeric micelles. Biomacromolecules, 6(5), 2462-2467.

Mori S, Matsuura A, Rama Prasad YV and Takada K. (2004). Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biological and Pharmaceutical Bulletin, 27(3), 418-421.

Tuylek Z. (2017). Drug delivery systems and nanotechnological interaction. Bozok Medical Journal, 7(3), 89-98.

Vasir JK and Labhasetwar V. (2005). Targeted drug delivery in cancer therapy. Technology in Cancer Research and Treatment, 4(4), 363-374.

Onoue S, Sato H, Ogawa K, Kojo Y, Aoki Y, Wada K, Mizumoto T and Yamada S. (2012). Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats. European Journal of Pharmaceutics and Biopharmaceutics, 80(1), 54-60.

Celik M. (2014). Drug targeting techniques in pharmaceutical biotechnology. Ph.D. thesis, University of Erciyes, Kayseri.

Cushing BL, Kolesnichenko VL and O'Connor CJ. (2004). Recent advances in the liquid-phase syntheses of inorganic nanoparticles. Chemical Reviews, 104(9), 3893-3946.

Derman S, Kizilbey K and Akdeste ZM. (2013). Polymeric nanoparticles. Journal of Engineering and Natural Sciences, 31, 107-120.

Zhang Y, Zhai M, Chen Z, Han X, Yu F, Li Z, Xie X, Han C, Yu L, Yang Y and Mei X. (2017). Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Delivery, 24(1), 1045-1055.

Tomii Y. (2002). Lipid formulation as a drug carrier for drug delivery. Current Pharmaceutical Design, 8(6), 467-474.

Kawakami S, Yamamura K, Mukai T, Nishida K, Nakamura J, Sakaeda T, Nakashima M and Sasaki H. (2001). Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. Journal of Pharmacy and Pharmacology, 53(8), 1157-1161.

Fetterly GJ and Straubinger RM. (2003). Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSciTech, 5(4), 1-11.

Barenholz Y. (2012). Doxil® the first FDA approved nano-drug: lessons learned. The Journal of Controlled Release, 160(2), 117-134.

Morikawa A. (2016). Comparison of properties among dendritic and hyperbranched poly(ether ether ketone)s and linear poly(ether ketone)s. Molecules, 21(2), 1-13.

Chauhan AS. (2015). Dendrimer nanotechnology for enhanced formulation and controlled delivery of resveratrol. Annals of the New York Academy of Sciences, 1348(1), 134-140.

Kaushik A, Tiwari S, Jayant RD, Vashist A, Nikkhah-Moshaie R, El-Hage N and Nair M. (2017). Electrochemical biosensors for early stage Zika diagnostics. Trends in Biotechnology, 35(4), 308-317.

Kiraz M, Cevik S, Demirel A, Gergin YE and Ozdemir O. (2018). Nanotechnology and nanoneurosurgery. Turkish Journal of Neurochirurgie, 28(3), 264-272.

Chen Y and Yang K. (2012). Intra-articular drug delivery systems for arthritis treatment. Rheumatology, 2(2), 1-2.

Barakat NS, Bin Taleb DA and Al Salehi AS (2012). Target nanoparticles: an appealing drug delivery platform. Journal of Nanomedicine and Nanotechnology, 1-9.

Romero EL. (2012). The involvement of nano-drug delivery in biosafety issues. Biosafety, 1(2), 1-5.

Anwunobi AP and Emeje MO. (2012). Recent applications of natural polymers in nanodrug delivery. Journal of Nanomedicine and Nanotechnology, 4, 1-6.

Torchilin VP. (2001). Structure and design of polymeric surfanctant-based drug delivery systems. The Journal of Controlled Release, 73(2-3), 137-172.

Zhang X, Huang Y and Li S. (2014). Nanomicellar carriers for targeted delivery of anticancer agents. Therapeutic Delivery, 5(1), 53-68.

Sayiner O and Comoglu T. (2016). Targeting with nanocarrier systems. Journal of Faculty of Pharmacy of Ankara University, 40(3), 62-79.

Yadav HKS, Al Halabi NA and Alsalloum GA. (2017). Nanogels as novel drug delivery systems-a review. Journal of Pharmacy and Pharmaceutical Research, 1, 1-8.

Sultana F, Manirujjaman, Imran-Ul-Haque Md, Arafat M and Sharmin S. (2013). An overview of nanogel drug delivery system. Journal of Applied Pharmaceutical Science, 3, 95-105.

Mader K. (2006). Solid Lipid Nanoparticles as Drug Carriers. In: Torchilin VP (Eds), Nanoparticulates as drug carriers. Imperial College Press, London, UK, 187-212.

Abaee A and Madadlou A. (2016). Niosome-loaded cold-set whey protein hydrogels. Food Chemistry, 196, 106-113.

Makeshwar KB and Wasankar SR. (2013). Niosome: a novel drug delivery system. Asian Journal of Pharmaceutical Research, 16-20.

Mason TG, Wilking JN, Meleson K, Chang CB and Graves SM. (2006). Nanoemulsions: formation, structure and physical properties. Journal of Physiscs-Condensed. Matter, 18, 635-666.

McClemments J, Takhistov P and Weiss J. (2006). Functional materials in food nanotechnology. Journal of Food Science, 71(9), 107-116.

Sezgin Z, Yuksel N and Baykara T. (2003). Preparation and characterization of polymeric micelles as drug carrier system. Journal of Faculty of Pharmacy of Ankara University, 32(2), 125-142.

Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation, 41, 189-207.

Choi SH, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG and Frangioni JV. (2007). Renal clearance of quantum dots. Nature Biotechnology, 25, 1165-1170.

Venturoli D and Rippe B. (2005). Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. American Journal of Physiology Renal Physiology, 288(4), 605-613.

Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Terada Y, Kano MR, Miyazono K, Uesaka M, Nishiyama N and Kataoka K. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nature Nanotechnology, 6, 815-823.

Redhead HM, Davis SS and Illum L. (2001). Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. The Journal of Controlled Release, 70, 353-363.

Singh R and Lillard JR. (2009). Nanoparticle based drug delivery. Experimental and Molecular Pathology, 215-223.

Parveen S, Misra R and Saho SK. (2012). Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine, 8(2), 147-166.

Danhier F, Feron O and Préat V. (2010). To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.

Perez Herrero E and Fernandez Medarde A. (2015). Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 52-70.

Torchilin V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 63(3), 131-135.

Bae Y and Park K. (2011). Targeted drug delivery to tumors: myths, reality and possibility. The Journal of Controlled Release, 153(3), 198-205.

Baudino TA. (2015). Targeted cancer therapy: the next generation of cancer treatment. Current Drug Discovery Technologies, 12(1), 3-20.

Rizvi SAA and Sale AM. (2018). Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical Journal, 26, 64-70.

Somani S and Dufes C. (2014). Applications of dendrimers for brain delivery and cancer therapy. Nanomedicine (Lond), 9(15), 2403-2414.

Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J and Baker JR. (2002). Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharmaceutical Research, 19(9), 1310-1316.

Dinesh B, Bianco A and Menard-Moyon C. (2016). Designing multimodal carbon nanotubes by covalent multi-functionalization. Nanoscale, 8(44), 18596-18611.

Zhang Q, Yang W, Man N, Zheng F, Shen Y, Sun K, Li Y and Wen LP. (2009). Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal. Autophagy, 5(8), 1107-1117.

Arafa MG, El-Kased RF and Elmazar MM. (2018). Thermoresponsive gels containing gold nanoparticles as smart antibacterial and wound healing agents. Scientific Reports, 8, 1-15.

Sanad RA and Abdel-Bar HM. (2017). Chitosan-hyaluronic acid composite sponge scaffold enriched with andrographolide-loaded lipid nanoparticles for enhanced wound healing. Carbohydrate Polymers, 173, 441-450.

Singh L, Kruger HG and Maguire GEM. (2017). The role of nanotechnology in the treatment of viral infecions. Therapeutic Advances in Infectious Disease, 4(4), 105-131.

Chiodo F, Marradi M, Calvo J, Yuste E and Penades S. (2014). Glycosystems in nanotechnology: gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein Journal of Organic Chemistry, 10, 1339-1346.

Sakaguchi S, Yamaguchi T, Nomura T and Ono M. (2008). Regulatory T cells and immune tolerance. Cell, 133(5), 775-787.

Méndez-Lagares G, Jaramillo-Ruiz D, Pion M, Pion M, Leal M, Muñoz-Fernández MA, Pacheco YM and Correa-Rocha R. (2014). HIV infection deregulates the balance between regulatory T cells and IL-2-producing CD4 T cells by decreasing the expression of the IL-2 receptor in Treg. Journal of Acquired Immune Deficiency Syndromes, 65(3), 278-282.

Jaramillo-Ruiz D, De La Mata FJ, Gómez R, Correa-Rocha R and Muñoz-Fernández MA. (2016). Nanotechnology as a new therapeutic approach to prevent the HIV-infection of Treg cells. PLos One, 11(1), 1-15.

Wang J, Feng SS, Wang S and Chen ZY. (2010). Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. International Journal of Pharmaceutics, 400(1-2), 194-200.

Lebre F, Borchard G, Faneca H, Pedroso de Lima MC and Borges O. (2016). Intranasal administration of novel chitosan nanoparticle/DNA complexes induces antibody response to hepatitis B surface antigen in mice. Molecular Pharmaceutics, 13(2), 472-482.

Moon JS, Lee SH, Han SH, Kim EJ, Cho H, Lee W, Kim MK, Kim TE, Park HJ, Rhee JK, Kim SJ, Cho SW, Han SH and Oh JW. (2016). Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2. Nanomedicine, 12(6), 1489-1498.

Sjogren MH. (2005). Prevention of hepatitis B in non-responders to initial hepatitis B virus vaccination. The American Journal of Medicine, 118, 34-39.

Arya AK, Kumar L, Pokharia D and Tripathi K. (2008). Applications of nanotechnology in diabetes. Digest Journal of Nanomaterials and Biostructures, 3(4), 221-225.

Cui F, Qian F, Zhao Z, Yin L, Tang C and Yin C. (2009). Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly (methyl methacrylate) nanoparticles. Biomacromolecules, 10(5), 1253-1258.

Harsoliya MS, Patel VM, Modasiya M, Pathan JK, Chauhan A, Parihar M and Ali M. (2012). Recent advances and applications of nanotechnology in diabetes. International Journal of Pharmaceutical and Biological Archive, 3, 255-261.

Meetoo D and Lappin M. (2009). Nanotechnology and the future of diabetes management. Journal of Diabetes Nursing, 13(8), 288-297.

Gordon N. (2003). Sagman, U. Nanomedicine taxonomy. Briefing paper.

Hanazaki K, Nose Y and Brunicardi FC. (2001). Artificial endocrine pancreas. Journal of the American College of Surgeons, 193(3), 310-322.

Freitas RA. (2005). Current status of nanomedicine and medical nanorobotics. Journal of Computational and Theoretical Nanoscience, 2, 1-25.

Chanda AV and Unnikrishnan V. (2018). Novel insole design for diabetic foot ulcer management. Proceedings of the Institution of Mechanical Engineers, Part H, 232(12), 1182-1195.

Sahoo SK, Parveen S and Panda JJ. (2007). The present and future of nanotechnology in human health care. Nanomedicine, 3(1), 20-31.

Naschie MSE. (2006). Nanotecnology for the devoloping world. Chaos, Solution and Fractals, 30(4), 769-773.

Lafisco M, Ruffini A, Adamiano A, Sprio S and Tampieri A. (2014). Biomimetic magnesium-carbonate-apatite nanocrystals endowed with strontium ions as anti-osteoporotic trigger. Materials Science and Engineering: C, 35, 212-219.

Balasundaram G and Webster TJ. (2010). HA coated magnetic nanoparticles for the treatment of osteoporosis. 27(9).

Huang S, Chen JC, Hsu CW and Chang WH. (2009). Effects of nano calcium carbonate and nano calcium citrate on toxicity in ICR mice and on bone mineral density in an ovariectomized mice model. Nanotechnology, 20(37), 1-7.

Tokudome Y, Ito A and Otsuka M. (2011). Effect of zinc-containing β-tricalcium phosphate nano particles injection on jawbone mineral density and mechanical strength of osteoporosis model rats. Biological and Pharmaceutical Bulletin, 34(8), 1215-1218.